Stock BLISSGVS BLISS GVS PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Bliss GVS Pharma Limited Stock NSE India S.E.

Equities

BLISSGVS

INE416D01022

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:40:29 2024-07-16 am EDT 		5-day change 1st Jan Change
114.1 INR -1.66% Intraday chart for Bliss GVS Pharma Limited +2.35% -8.49%
Jun. 21 Office of the Joint Commissioner, Food and Drugs Administration Orders for Suspension of FDA License Issued to Tablet Division of Manufacturing Unit CI
Jun. 20 Crisil Keeps BBB+ Rating on Bliss GVS Pharma's Bank Loans; Outlook Stable MT

Financials

Sales 2023 7.52B 89.97M Sales 2024 7.7B 92.2M Capitalization 11.79B 141M
Net income 2023 709M 8.49M Net income 2024 755M 9.04M EV / Sales 2023 1.03 x
Net Debt 2023 335M 4.01M Net cash position 2024 405M 4.85M EV / Sales 2024 1.48 x
P/E ratio 2023
10.6 x
P/E ratio 2024
15.8 x
Employees 831
Yield 2023
0.7%
Yield 2024
0.44%
Free-Float 36.08%
More Fundamentals * Assessed data

Chart Bliss GVS Pharma Limited

Dynamic Chart

Latest news about Bliss GVS Pharma Limited

Office of the Joint Commissioner, Food and Drugs Administration Orders for Suspension of FDA License Issued to Tablet Division of Manufacturing Unit CI
Crisil Keeps BBB+ Rating on Bliss GVS Pharma's Bank Loans; Outlook Stable MT
Bliss GVS Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Bliss GVS Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Bliss Gvs Pharma Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024, Payable on or Before August 24, 2024 CI
Bliss GVS Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Bliss GVS Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Assistant Commission of State Tax Maharashtra, Mumbai Initiates Search At Certain Premises of Bliss GVS Pharma Limited CI
Bliss Gvs Pharma Limited Announces Change in the Designation of Mr. Vishal Vijay Rao CI
Bliss GVS Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Bliss GVS Pharma Limited Declares Final Dividend for the Financial Year Ended March 31, 2023 CI
Bliss GVS Pharma Gets Establishment Inspection Report from US FDA for Palghar, India Unit MT
Bliss Gvs Pharma Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023 CI
Bliss GVS Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Bliss GVS Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
More news

Press releases Bliss GVS Pharma Limited

Bliss GVS Pharma Presents Gh?150,000 Anti-Malaria Drugs to Hospitals AQ
More press releases

Quotes and Performance

1 day-1.66%
1 week+3.75%
Current month+12.36%
1 month+9.99%
3 months+1.67%
6 months-12.79%
Current year-8.49%
More quotes

Highs and lows

1 week
106.43
Extreme 106.43
120.70
1 month
101.01
Extreme 101.01
120.70
Current year
92.15
Extreme 92.15
142.40
1 year
77.35
Extreme 77.35
149.60
3 years
66.10
Extreme 66.1
149.60
5 years
66.10
Extreme 66.1
221.00
10 years
43.40
Extreme 43.4
221.00
More quotes

Managers and Directors - Bliss GVS Pharma Limited

Managers TitleAgeSince
Gagan Harsh Sharma CEO
 Chief Executive Officer 41 21-01-20
Deepak Sawant DFI
 Director of Finance/CFO 44 22-12-29
Aditi Himanshu Bhatt CMP
 Compliance Officer - 15-11-08
Members of the board TitleAgeSince
Subramanian R. Vaidya CHM
 Chairman 81 11-07-31
Vibha Gagan Sharma BRD
 Director/Board Member 41 08-07-28
Shruti Vishal Rao BRD
 Director/Board Member 39 06-07-26
More insiders

Quotes

Date Price Change Volume
24-07-16 114.1 -1.66% 258 211
24-07-15 116 +0.50% 690,919
24-07-12 115.4 -0.92% 1,562,390
24-07-11 116.5 +5.47% 2,488,080
24-07-10 110.4 +0.45% 367,306

Delayed Quote NSE India S.E., July 16, 2024 at 07:40 am EDT

More quotes

Company Profile

Bliss GVS Pharma Limited is engaged in developing, manufacturing, and marketing pharmaceutical formulations. The Company’s product categories include pharma products and other healthcare products. Its pharma products include pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, soft gelatine capsules and syrups. The Company’s other healthcare products include balm, nasal inhaler, solution, soap, vaginal wash, roll on, shampoo, powder, spray, and petroleum jelly. Its brands include ANOMEX, ANOMEX DS, CONLAX 5/10, G - ALFENAC 100, GACET 80/125/170/250/500/1G, GMETH - 50/100, GSUNATE - 50/100/200, GVCAM - 7.5/15, GV-SOFT 1/2/3/4 G, LOFNAC - 12.5/25/50/100, MEFINOL, MELANEZ, MENINA - 25/100, TYRIDOL, VIGOTAMIN, COMIT 50, BG - CLIND, VAGID CL, ECOZOLE, GVGYL 500, GYNANFORT, GVGYL N, KLOVINAL, LONART, LONART FORTE, LONART Dispersible, FINMOL, GACET-500, and DOXYCYCLINE.
Sector
Pharmaceuticals
Calendar
2024-07-17 - Détachement de for final dividend
More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

1st Jan change Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+25.40% 45.54B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+34.52% 24.51B
SANDOZ GROUP AG Stock Sandoz Group AG
+26.83% 16.48B
CIPLA LIMITED Stock Cipla Limited
+21.19% 14.66B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+71.91% 14.3B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-11.84% 6.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+18.15% 5.87B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BLISSGVS Stock
  4. BLISSGVS Stock